Tokushima-ken, Japan

Chieko Kunugita


Average Co-Inventor Count = 8.9

ph-index = 3

Forward Citations = 57(Granted Patents)


Location History:

  • Tokushima-ken, JP (1997)
  • Tokushima, JP (1999)
  • Itano-gun, JP (1999)

Company Filing History:


Years Active: 1997-1999

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Chieko Kunugita: Innovator in Beta-Lactamase Inhibitors

Introduction

Chieko Kunugita is a prominent inventor based in Tokushima-ken, Japan. She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit bacterial beta-lactamases. With a total of three patents to her name, her work has the potential to enhance the effectiveness of beta-lactam antibiotics.

Latest Patents

Her latest patents include innovative azetidinone derivatives that serve as beta-lactamase inhibitors. One notable patent describes new 2-oxo-1-azetidine sulfonic acid derivatives featuring an aminoalkyl substituted 'anti' (E-isomer) oxyimino group. These compounds are recognized for their potency in inhibiting bacterial beta-lactamases. Additionally, they can be used in conjunction with beta-lactam antibiotics to improve their efficacy against infections caused by beta-lactamase producing bacteria.

Career Highlights

Throughout her career, Chieko has worked with reputable companies such as Synphar Laboratories, Inc. and Taiho Pharmaceutical Company Limited. Her experience in these organizations has allowed her to develop her expertise in pharmaceutical innovations and contribute to significant advancements in the field.

Collaborations

Chieko has collaborated with notable colleagues, including Samarendra N Maiti and Oludotun A Phillips. These partnerships have further enriched her research and development efforts in the pharmaceutical industry.

Conclusion

Chieko Kunugita's work in developing beta-lactamase inhibitors showcases her innovative spirit and dedication to improving antibiotic effectiveness. Her contributions are vital in the ongoing battle against antibiotic resistance.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…